FDA Approved Eye Drops: Lenz Therapeutics Launches VIZZ for Presbyopia Treatment
LENZ Therapeutics has secured FDA approval for VIZZ (aceclidine ophthalmic solution) 1.44%. These are the first FDA-approved eye drops designed to treat presbyopia in adults. They offer a once-daily improvement of near vision for up to 10 hours, and target approximately 128 million affected Americans. The company plans to distribute samples by October 2025, and broad commercial availability is expected by mid-Q4 2025. This approval marks a major advancement in non-surgical presbyopia management. Clinical trials support its efficacy and safety, with mild, transient reactions like irritation and temporary dim vision.
Key Insights:
VIZZ’s mechanism focuses on pupil-selective miosis with minimal ciliary muscle activation which creates a pinhole effect to enhance depth of focus. Unlike prior approaches, it avoids side effects like brow heaviness. Clinical data showed 20% of users had mild irritation, 16% reported dim vision, and 13% had headaches. Nearly all adverse events resolved spontaneously. VIZZ could transform a market limited to glasses, contacts, or surgery – as the first daily treatment with 10-hour efficacy, it meets unmet needs for convenience.
Presbyopia is an age-related condition caused by lens hardening and reduced ciliary muscle function. It affects nearly all adults over 50, typically starting around age 40. It impairs daily functioning for over 1 billion people globally, and in low-resource settings there are productivity challenges due to limited access to corrective lenses. Historically, treatments were optical solutions like reading glasses or invasive procedures. Until VIZZ, there were no FDA-approved pharmacologic therapies for presbyopia.
Implications:
VIZZ’s approval could shift presbyopia management by reducing demand for reading glasses and surgical corrections. This could change vision care cost structures. Daily dosing may improve adherence and quality of life compared to traditional aids. Payers may establish new reimbursement models for vision-correcting medications.
For further details, refer to the press release by Lenz Therapeutics.
